论文部分内容阅读
目的:探讨磁共振扩散加权成像(DWI)和动态增强成像(DCEI)后测量的信号增强率(SER)在评价肝脏原发癌(PhC)立体定向放射治疗后的疗效,并探讨两者的关联性。方法:收集确诊肝癌病人34例,分别于放射治疗前、放射治疗15天、治疗完成、完成后1个月、完成后3个月时行磁共振DWI和动态增强检查,比较各期病灶大小、ADC值以及SER的差异,分析放射治疗后ADC值改变与SER改变之间的关联性。结果:肝癌在立体定向放射治疗早期体积无明显变化,放射治疗前、放射治疗15天、治疗完成、完成后1个月、完成后3个月ADC值:(1.053士0.194)×10-3mm2/s,(1.059士0.146)×10-3mm2/s;(1.104士0.129)×10-3mm2/s;(1.167士0.185)×10-3mm2/s;(1.244士0.133)×10-3mm2/s。SER:127.55±22.32;122.91±22.80;108.59±23.10;;83.36±23.55;47.61±22.36。结论:肝癌在立体定向放射治疗后各期的ADC值与DCEI测量的SER存在一定的关系,两者结合有助于肝癌立体定向放射治疗的疗效评价。
OBJECTIVE: To investigate the effect of signal enhancement (SER) measured after DWI and DCEI on evaluating the efficacy of stereotactic radiotherapy for primary liver cancer (PhC) and to explore their relationship Sex. Methods: Totally 34 patients with confirmed liver cancer were collected. Before radiation therapy, 15 days after radiotherapy, the treatment was completed, 1 month after completion and 3 months after the completion of magnetic resonance DWI and dynamic contrast-enhanced examination. The size, ADC value and the difference of SER, and analyzed the relationship between the change of ADC value and the change of SER after radiotherapy. Results: There was no significant change in the volume of HCC in the early stage of stereotactic radiotherapy. Radiotherapy was performed for 15 days before radiotherapy, and the treatment was completed. One month after the completion of the treatment, the ADC value at 3 months after the completion of treatment was (1.053 ± 0.194) × 10-3mm2 / (1.059 ± 0.146) × 10-3mm2 / s; (1.104 ± 0.129) × 10-3mm2 / s; (1.167 ± 0.185) × 10-3mm2 / s; (1.244 ± 0.133) × 10-3mm2 / s. SER: 127.55 ± 22.32; 122.91 ± 22.80; 108.59 ± 23.10 ;; 83.36 ± 23.55; 47.61 ± 22.36. Conclusion: There is a certain relationship between the ADC value and the SER measured by DCEI in patients with hepatocellular carcinoma at different stages after stereotactic radiotherapy. The combination of the two can be helpful to the curative effect of stereotactic radiotherapy for hepatocellular carcinoma.